Drug Profile
Measles and rubella vaccine - Biological E. Limited/Takeda
Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator Biological E Limited
- Developer Biological E Limited; Takeda
- Class Measles vaccines; Rubella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Measles; Rubella
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Measles(Prevention) in India (Parenteral, Injection)
- 28 Jul 2021 No recent reports of development identified for research development in Rubella(Prevention) in India (Parenteral, Injection)
- 26 Jun 2017 Biological E Limited in-licenses measles vaccine technology from Takeda